Results 11 to 20 of about 5,587,889 (314)

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

New England Journal of Medicine, 2016
BACKGROUND Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk.
S. Marso, S. Bain, A. Consoli, F. Eliaschewitz, E. Jódar, Lawrence A Leiter, I. Lingvay, J. Rosenstock, J. Seufert, M. Warren, V. Woo, O. Hansen, A. Holst, Jonas Pettersson, T. Vilsbøll   +14 more
semanticscholar   +1 more source

Economic Costs of Diabetes in the U.S. in 2022.

Diabetes Care, 2023
OBJECTIVE This study updates previous estimates of the economic burden of diagnosed diabetes, with calculation of the health resource use and indirect costs attributable to diabetes in 2022.
Emily D Parker, Janice Lin, Troy Mahoney, Nwanneamaka Ume, Grace Yang, Robert A. Gabbay, Nuha A. ElSayed, Raveendhara R. Bannuru   +7 more
semanticscholar   +1 more source

Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? [PDF]

, 2013
In this review, we explore the concept of ‘double diabetes’, a combination of type 1 diabetes with features of insulin resistance and type 2 diabetes.
A Caixas, AM Taylor, B Conway, B Teupe, B. M. Fisher, BF Voight, CT Prince, D Williams, D Yazici, DB Savage, DM Maahs, DM Maahs, DM Nathan, EA Nikkila, ER Christ, ES Kilpatrick, G Pambianco, G Perseghin, G Perseghin, G Roglic, G Ruotolo, H. M. Colhoun, HM Colhoun, IE Schauer, J Frystyk, J Guy, J Yip, J-L Selam, J. R. Petrie, JA Edge, JB Ferriss, JC Zgibor, JQ Purnell, JQ Purnell, JR Erbey, JR Petrie, JT Lahtela, KJ Nadeau, L Hodson, LM Thorn, M Kacerovsky, MR Taskinen, MR Taskinen, MR Taskinen, N Chaturvedi, N Sattar, N. Sattar, P Nevalainen, P Petruzzo, R Sinha, RA Heptulla, RW James, S Makimattila, S Norbert, S Vella, S. J. Cleland, SC Bain, SD Sibley, SJ Livingstone, SR Vethakkan, The Diabetes Control and Complications Trial Research Group, TJ Orchard, TJ Wilkin   +62 more
core   +3 more sources

Prevalence of pre-diabetes and undiagnosed diabetes in the Mollerussa prospective observational cohort study in a semi-rural area of Catalonia [PDF]

, 2020
Objectives: To assess the prevalence of undiagnosed diabetes and pre-diabetes in the healthy population in the Mollerussa cohort. As a secondary objective, to identify the variables associated with these conditions and to describe the changes in ...
Alcubierre, N., Castelblanco, Esmeralda, Cebrian, C., Falguera, M., Franch-Nadal, J., Granado-Casas, Minerva, Marsal, Josep Ramon, Mata-Cases, Manel, Mauricio Puente, Dídac, Miró, N., Molló, À., Universitat Autònoma de Barcelona, Vilanova, M.B.   +12 more
core   +3 more sources

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

New England Journal of Medicine, 2015
BACKGROUND The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.
B. Zinman, C. Wanner, J. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O. Johansen, H. Woerle, U. Broedl, S. Inzucchi   +11 more
semanticscholar   +1 more source

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Diabetes Care, 2022
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated ...
M. Davies, V. Aroda, B. Collins, R. Gabbay, Jennifer B. Green, N. Maruthur, Sylvia E. Rosas, S. Del Prato, C. Mathieu, G. Mingrone, P. Rossing, T. Tankova, A. Tsapas, J. Buse   +13 more
semanticscholar   +1 more source

Algorithm and Related Application for Smart Wearable Devices to Reduce the Risk of Death and Brain Damage in Diabetic Coma [PDF]

J Diabetes Sci Technol May 2016 vol. 10 no. 3 802-803, 2015
Diabetes is an epidemic disease of the 21st century and is growing globally. Although, final diabetes treatments and cure are still on research phase, related complications of diabetes endanger life of diabetic patients. Diabetic coma which happens with extreme high or low blood glucose is one of the risk factor for diabetic patients and if it remains ...
arxiv   +1 more source

Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms [PDF]

, 2018
Hypertension and type 2 diabetes are common comorbidities. Hypertension is twice as frequent in patients with diabetes compared with those who do not have diabetes.
Guzik, Tomasz J., Petrie, John R., Touyz, Rhian M.   +2 more
core   +1 more source

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

Diabetes Care, 2004
OBJECTIVE The goal of this study was to estimate the prevalence of diabetes and the number of people of all ages with diabetes for years 2000 and 2030.
S. Wild, G. Roglić, A. Green, R. Sicree, H. King   +4 more
semanticscholar   +1 more source

Codesigned Shared Decision-Making Diabetes Management Plan Tool for Adolescents With Type 1 Diabetes Mellitus and Their Parents: Prototype Development and Pilot Test [PDF]

, 2018
Background: Adolescents with type 1 diabetes mellitus have difficulty achieving optimal glycemic control, partly due to competing priorities that interfere with diabetes self-care.
Carroll, Aaron E., Cheng, Erika R., Claxton, Gina E. M., Hannon, Tamara S., Lynch, Dustin O., Moore, Courtney M., Wiehe, Sarah E., Yazel-Smith, Lisa G.   +7 more
core   +1 more source